...
crvs-img

Corvus Pharmaceuticals Inc, Common Stock

CRVS

NMQ

$3.848

-$3.54

(-47.9%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$443.38M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
7.91M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.04
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.3 L
$10 H
$3.848

About Corvus Pharmaceuticals Inc, Common Stock

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCRVSSectorS&P500
1-Week Return-7.86%-3.39%0.2%
1-Month Return-11.39%-1.92%2.72%
3-Month Return34.36%-10.54%7.31%
6-Month Return282.9%-4.47%10.44%
1-Year Return379.87%4.06%27.53%
3-Year Return170.7%0.94%30.88%
5-Year Return82.02%36.67%89.21%
10-Year Return-48.14%102.87%199.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue743.00K632.00K460.00K367.00K151.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":85.06,"profit":true},{"date":"2021-12-31","value":61.91,"profit":true},{"date":"2022-12-31","value":49.39,"profit":true},{"date":"2023-12-31","value":20.32,"profit":true}]
Gross Profit(743.00K)(632.00K)(460.00K)(367.00K)(151.00K)[{"date":"2019-12-31","value":-74300000,"profit":false},{"date":"2020-12-31","value":-63200000,"profit":false},{"date":"2021-12-31","value":-46000000,"profit":false},{"date":"2022-12-31","value":-36700000,"profit":false},{"date":"2023-12-31","value":-15100000,"profit":false}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses48.85M43.76M38.63M32.56M23.41M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":89.57,"profit":true},{"date":"2021-12-31","value":79.07,"profit":true},{"date":"2022-12-31","value":66.66,"profit":true},{"date":"2023-12-31","value":47.91,"profit":true}]
Operating Income(48.85M)(43.76M)(38.63M)(32.56M)(23.33M)[{"date":"2019-12-31","value":-4885400000,"profit":false},{"date":"2020-12-31","value":-4376000000,"profit":false},{"date":"2021-12-31","value":-3863000000,"profit":false},{"date":"2022-12-31","value":-3256500000,"profit":false},{"date":"2023-12-31","value":-2332900000,"profit":false}]
Total Non-Operating Income/Expense4.36M38.30M(4.63M)(8.09M)(2.18M)[{"date":"2019-12-31","value":11.39,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-12.08,"profit":false},{"date":"2022-12-31","value":-21.11,"profit":false},{"date":"2023-12-31","value":-5.69,"profit":false}]
Pre-Tax Income(46.67M)(6.00M)(43.24M)(41.31M)(27.03M)[{"date":"2019-12-31","value":-4667200000,"profit":false},{"date":"2020-12-31","value":-599500000,"profit":false},{"date":"2021-12-31","value":-4324100000,"profit":false},{"date":"2022-12-31","value":-4130700000,"profit":false},{"date":"2023-12-31","value":-2702900000,"profit":false}]
Income Taxes(2.92M)(1.17M)(5.04M)8.74M-[{"date":"2019-12-31","value":-33.46,"profit":false},{"date":"2020-12-31","value":-13.41,"profit":false},{"date":"2021-12-31","value":-57.66,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(43.75M)(4.82M)(38.20M)(50.05M)-[{"date":"2019-12-31","value":-4374700000,"profit":false},{"date":"2020-12-31","value":-482300000,"profit":false},{"date":"2021-12-31","value":-3820000000,"profit":false},{"date":"2022-12-31","value":-5004900000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(46.67M)(6.00M)(43.24M)(41.31M)(30.19M)[{"date":"2019-12-31","value":-4667200000,"profit":false},{"date":"2020-12-31","value":-599500000,"profit":false},{"date":"2021-12-31","value":-4324100000,"profit":false},{"date":"2022-12-31","value":-4130700000,"profit":false},{"date":"2023-12-31","value":-3019200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(43.75M)(4.82M)(38.20M)(50.05M)(27.03M)[{"date":"2019-12-31","value":-4374700000,"profit":false},{"date":"2020-12-31","value":-482300000,"profit":false},{"date":"2021-12-31","value":-3820000000,"profit":false},{"date":"2022-12-31","value":-5004900000,"profit":false},{"date":"2023-12-31","value":-2702900000,"profit":false}]
EPS (Diluted)(1.59)(1.46)(1.06)(0.89)(0.57)[{"date":"2019-12-31","value":-159,"profit":false},{"date":"2020-12-31","value":-146,"profit":false},{"date":"2021-12-31","value":-106,"profit":false},{"date":"2022-12-31","value":-89,"profit":false},{"date":"2023-12-31","value":-57,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CRVS
Cash Ratio 0.90
Current Ratio 0.92

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CRVS
ROA (LTM) -23.83%
ROE (LTM) -44.91%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CRVS
Debt Ratio Lower is generally better. Negative is bad. 0.79
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.21

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CRVS
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 35.73
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.36
PEG NM

FAQs

What is Corvus Pharmaceuticals Inc share price today?

Corvus Pharmaceuticals Inc (CRVS) share price today is $3.848

Can Indians buy Corvus Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Corvus Pharmaceuticals Inc (CRVS) on Vested. To buy Corvus Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CRVS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Corvus Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Corvus Pharmaceuticals Inc (CRVS) via the Vested app. You can start investing in Corvus Pharmaceuticals Inc (CRVS) with a minimum investment of $1.

How to invest in Corvus Pharmaceuticals Inc shares from India?

You can invest in shares of Corvus Pharmaceuticals Inc (CRVS) via Vested in three simple steps:

  • Click on Sign Up or Invest in CRVS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Corvus Pharmaceuticals Inc shares
What is Corvus Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Corvus Pharmaceuticals Inc (CRVS) is $10. The 52-week low price of Corvus Pharmaceuticals Inc (CRVS) is $1.3.

What is Corvus Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Corvus Pharmaceuticals Inc (CRVS) is

What is Corvus Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Corvus Pharmaceuticals Inc (CRVS) is 35.73

What is Corvus Pharmaceuticals Inc dividend yield?

The dividend yield of Corvus Pharmaceuticals Inc (CRVS) is 0.00%

What is the Market Cap of Corvus Pharmaceuticals Inc?

The market capitalization of Corvus Pharmaceuticals Inc (CRVS) is $443.38M

What is Corvus Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Corvus Pharmaceuticals Inc is CRVS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top